JUN and prostate cancer: Activation of both, ERK and c-JUN are observed in LNCaP and PC3 cells after treatment with GT3 but not AT. It has been reported that GT3 activates the c-JUN N-terminal kinase JNK signaling pathway in prostate cancer cells, with the subsequent phosphorylation of c-JUN [9].